Quick Facts on Therapeutic Domains

• Contraception: Used for the prevention of pregnancy.
• Skin and Hair: May assist in the management of specific androgen-related symptoms such as acne, seborrhea, and hirsutism.

Neo-Eunomin is a prescribed medication utilized to provide contraception (prevention of pregnancy). The inclusion of progestational hormones in the formulation works to help regulate the menstrual cycle and prevent conception.

Furthermore, this therapeutic approach may also be applied in the management of certain androgenization symptoms that affect the skin and hair. Clinical observation suggests that it may contribute to the improvement of conditions such as acne and seborrhea. A key therapeutic domain includes its use in supporting the reduction of excessive hair growth, known as hirsutism.

Neo-Eunomin, which contains chlormadinone acetate and ethinyl estradiol, is used in addressing these symptoms.

Eligibility Map: Who can and cannot use Neo-Eunomin — official regulatory information

The eligibility profile for Neo-Eunomin (Chlormadinone Acetate/Ethinyl Estradiol) is defined exclusively by official regulatory documents, specifying populations for whom use is prohibited (contraindicated) or restricted.

---

Eligibility scope

Populations for whom use is allowed (as stated in label):

• Females of childbearing potential (post-menarche).

Populations for whom use is contraindicated:

• Current or history of Venous or Arterial Thromboembolism (VTE/ATE), including deep vein thrombosis, pulmonary embolism, stroke, or myocardial infarction.
• Known or suspected pregnancy or lactation (breastfeeding).
• Current or history of hormone-sensitive malignancy (e.g., breast cancer) or Meningioma.
• Severe liver disease or liver function disorders until values have returned to normal.
• Severe uncontrolled hypertension or diabetes mellitus with vascular complications.
• Concomitant use with specific Hepatitis C antiviral regimens (e.g., ombitasvir/paritaprevir/ritonavir).

Age-related eligibility rules:

• Use is restricted to the post-menarche period.
• The medicine is not indicated after menopause.

Eligibility-related restrictions:

• Use must be discontinued four weeks prior to and two weeks following any major surgery requiring prolonged immobilization.

---

Connection to the overall eligibility profile

Official regulatory documents establish who may use the medicine by defining absolute exclusions using the term "contraindicated." These exclusions are based on critical health risks, such as a history of thromboembolic events, certain cancers, and severe organ dysfunction. Eligibility is also restricted based on physiological state (pregnancy, lactation) and concurrent drug therapy.

Neo-Eunomin's components, ethinyl estradiol and ethynodiol diacetate, are susceptible to interactions with several categories of medicines. The primary concern is the potential for reduced contraceptive efficacy, which is largely driven by pharmacokinetic mechanisms.

Documented Interacting Medicinal Products and Classes

The most clinically significant interactions involve medicines that are potent enzyme inducers, notably those affecting the cytochrome P450 system in the liver. These agents, which include specific anticonvulsants (e.g., phenytoin, carbamazepine, phenobarbital), the antibiotic rifampicin, and the herbal product St. John's Wort (Hypericum perforatum), accelerate the breakdown and clearance of the contraceptive steroids. This may result in lower plasma concentrations and an increased risk of breakthrough bleeding and contraceptive failure.

Additionally, certain antibiotics, such as ampicillin and tetracyclines, are known to potentially interfere with the enterohepatic recirculation of the estrogen component, which may also reduce effectiveness. Use of these interacting substances often requires concurrent use of a non-hormonal barrier method during administration and for a specified period thereafter (e.g., 7 or 28 days).

Conversely, Neo-Eunomin can affect the metabolism of other co-administered drugs. For instance, it may inhibit the clearance of drugs like cyclosporine, potentially leading to increased concentrations and requiring therapeutic monitoring. It may also decrease the plasma level and effectiveness of other medicines, such as the anti-epileptic drug lamotrigine, by accelerating its clearance.

Neo-Eunomin functions as a combined oral contraceptive by modulating the hypothalamic-pituitary-ovarian (HPO) axis. The ethinylestradiol component provides a negative feedback signal to the hypothalamus, which decreases the pulsatile release of Gonadotropin-releasing hormone (GnRH). This action consequently suppresses the pituitary secretion of Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH).

The progestin component, dienogest, reinforces this inhibition, primarily by suppressing the LH surge necessary for ovulation. Dienogest also acts locally on the cervix, altering the quality and viscosity of the cervical mucus. This change reduces its permeability to sperm migration. Furthermore, the combination alters the endometrial lining, inducing changes that inhibit blastocyst implantation.

How to Use Neo-Eunomin

The usage of Neo-Eunomin, a combined hormonal contraceptive containing Chlormadinone Acetate 2 mg and Ethinyl Estradiol 0.03 mg, follows a standardized, cyclic regimen for oral administration. This regimen is designed to ensure consistent administration over time.

---

Official Administration Guidelines

Administration Scope	Detail
Route of administration	Oral (by mouth)
Dosing schedule	One film-coated tablet daily
Timing in relation to meals	Usually taken with or after food
Age-group administration rules	Indicated only for use after menarche; not indicated after menopause
Missed-dose rules	If the usual intake time is exceeded by more than 12 hours, specific procedural steps must be followed as detailed in the prescribing information.

---

Procedural Structure and Schedule

Administration follows a 28-day cyclic pattern. The standard regimen involves taking one active tablet daily for 21 consecutive days, followed by a 7-day tablet-free interval.

The treatment cycle is initiated by taking the first active tablet on Day 1 of the menstrual period (the first day of bleeding). To maintain consistent hormone levels, the tablet is taken at the same time every day, and the order directed on the blister pack should be followed.

The use is for long-term administration in continuous cycles, and procedures exist for delaying a withdrawal bleed by continuing immediately with a new blister pack without the planned 7-day pause. This structure describes the method of administration.

Research Evidence: Overview of Studies for Neo-Eunomin

Evidence for Use in Contraception

Research was evaluated in studies exploring the prevention of pregnancy. The evidence base includes Phase II and III clinical trials alongside large-scale, prospective non-interventional studies, which examine its use among broad cohorts of women in real-world settings. Research explored the measurement of contraceptive reliability (Pearl Index) and cycle stability (incidence of unscheduled bleeding). Data show patterns related to contraceptive reliability was observed in the studies. However, comparative evidence is lacking from dedicated head-to-head randomized controlled trials directly comparing the measured outcomes of this formulation against all other available combined oral contraceptives.

Evidence for Use in Managing Androgen-Related Symptoms

Research explored its potential in conditions characterized by fluctuating manifestations linked to androgens, or male hormones.

Clinical Trials for Acne Management

Research for outcomes linked to inflammatory states such as acne was evaluated in randomized controlled trials (RCTs). These trials monitored the change in the number of acne lesions in women with mild to moderate papulopustular acne. RCTs explored patterns of change in the group studied versus the placebo group on the measured outcomes. However, the results apply only to the populations studied, and evidence is limited for women with more severe forms of acne.

Observational Data for Hirsutism and Seborrhea

The evidence base for excessive hair growth (hirsutism) and greasy skin/hair condition (seborrhea) evidence quality varies across studies when compared to the structured RCTs for acne. Research for these conditions often relies on analysis of subgroups within larger trials. Findings were mixed across studies, demonstrating some variability in symptomatic change.

What Remains Uncertain or Under-Researched

Key gaps include the lack of dedicated, large-scale, randomized, placebo-controlled trials specifically targeting secondary symptoms like hirsutism. The follow-up durations were limited in many primary studies, meaning long-term effects are not fully established regarding the durability of symptomatic changes.

Key Studies & References

1. Comparison of Body Weight Change During Contraception With Belara and Yasmin (Ethinylestradiol/Chlormadinone Acetate vs. Ethinylestradiol/Drospirenone): A Randomized Control Trial

Common questions about Neo-Eunomin (FAQ)

Q: Is Neo-Eunomin considered a monophasic or multiphasic oral contraceptive?

A: Official product information states that Neo-Eunomin is a monophasic birth control pill. This means that each of the 21 active tablets contains the same fixed amount of both hormones, Chlormadinone Acetate and Ethinyl Estradiol.

Q: How long does it typically take for Neo-Eunomin to be fully effective as a contraceptive?

A: If the pill is started correctly on the first day of your menstrual period (Day 1), contraceptive protection is generally considered highly effective starting immediately. If the pill is started later in the cycle, official guidance requires the use of a non-hormonal barrier method for the first 7 days of taking the active tablets to help ensure efficacy.

Q: What are the most common side effects patients report when starting Neo-Eunomin?

A: Studies and regulatory data indicate that the most frequent side effects reported include headache, breast discomfort or pain, and intermenstrual bleeding or spotting. These common effects are often most noticeable when first beginning the medication.

Q: Is irregular spotting or breakthrough bleeding normal during the first month of taking Neo-Eunomin?

A: Yes, regulatory documents mention that irregular bleeding and spotting may occur, particularly during the initial cycles of use. It is often considered a transient effect as the body adjusts to the hormonal regimen.

Q: How quickly do common side effects like nausea or breast tenderness usually resolve?

A: Official product information suggests that non-serious adverse reactions, such as nausea and breast tenderness, are most frequent upon initiation of treatment. These effects may lessen or resolve with continued use as the body adapts to the hormones.

Q: Can Neo-Eunomin affect mood, and is a change in anxiety or depression common?

A: Official reports for hormonal contraceptives list depressed mood and depression as common side effects associated with this class of medication. For persistent mood changes, it is important to consult with a healthcare professional.

Q: Do many users experience weight change, such as weight gain or loss, while on Neo-Eunomin?

A: Official safety data lists weight increase as a common side effect of this medication. Weight decrease is sometimes listed as an uncommon or rare side effect.

Q: Are headaches or migraines a common concern for people on Neo-Eunomin?

A: Yes, headache is listed as a very common adverse reaction in official product information. Migraine is also typically listed as a common side effect associated with this medication.

Q: What should be done if a user experiences severe vomiting or diarrhea after taking the pill?

A: If vomiting or severe diarrhoea occurs within 3 to 4 hours of taking an active tablet, the pill's absorption may be compromised. Regulatory instructions state that in this event, it is important to refer to the specific directions for a missed pill as detailed in the official prescribing information.

Q: What does the patient information leaflet say about missing a single pill?

A: The official instructions provide two main rules. If a tablet is missed by less than 12 hours, the official advice is to take it as soon as remembered. If it is missed by more than 12 hours, protection may be reduced, and specific steps must be followed based on the week of the cycle.

Q: Is it common for acne to temporarily worsen when first starting Neo-Eunomin?

A: While the medication is researched for its potential in improving acne, acne itself is listed as a common side effect in regulatory documents. This classification can include a temporary initial worsening for some individuals before any potential benefits are seen.

Q: Can Neo-Eunomin be taken back-to-back to skip a period, and is this safe?

A: Official usage instructions provide a procedure for delaying a withdrawal bleed (your period) by immediately starting a new pack without the 7-day break. This procedure is described within the regulated usage guidelines, though individual health status should always be considered.

Q: Is Neo-Eunomin a high-dose or low-dose oral contraceptive?

A: Neo-Eunomin is considered a low-dose combined oral contraceptive. This classification is based on its content of 0.03 mg of Ethinyl Estradiol (the estrogen component).

Q: Why might a doctor prescribe Neo-Eunomin instead of a progestin-only pill (mini-pill)?

A: Neo-Eunomin is a combined pill, offering both estrogen and progestin effects, which generally results in a high efficacy rate for contraception. Furthermore, it is specifically licensed for the treatment of moderate acne due to its antiandrogenic properties.

Q: Can taking Neo-Eunomin increase sensitivity to the sun or UV rays?

A: The official product information lists chloasma (darkening of the skin, often on the face) as a possible adverse reaction. Official guidance often includes the recommendation to limit exposure to the sun or UV radiation to prevent or minimize this effect.

Q: Does Neo-Eunomin have any known effects on libido or sex drive?

A: Yes, official safety data lists decreased libido (sex drive) as a common side effect associated with the use of this medication.

Q: What kind of changes can be expected in the menstrual period while using Neo-Eunomin?

A: Studies show that you can expect a controlled withdrawal bleed during the hormone-free week. Additionally, intermenstrual bleeding or spotting is a common change, especially during the first few cycles.

Q: Does Neo-Eunomin affect vitamin or nutrient absorption in the body?

A: Regulatory information indicates that the use of combined oral contraceptives may affect the metabolism or plasma concentrations of certain vitamins, such as folate, in the body.

Q: What happens to fertility after a person stops taking Neo-Eunomin?

A: Official warnings state that normal ovulatory cycles generally return rapidly once the medication is stopped. This indicates that normal fertility can return after the medication is stopped.

Q: Is there a higher risk of developing yeast infections while taking Neo-Eunomin?

A: Yes, Vaginal candidiasis (a type of yeast infection) is listed as an adverse reaction in the regulatory documents, typically classified as common or uncommon.

Q: What are the ingredients in the inactive (placebo) pills of Neo-Eunomin?

A: The inactive tablets contain no active hormones. They are made up of excipients (non-medicinal ingredients) necessary for the tablet form, such as lactose and other coating agents.

Q: What are the different strengths or formulations of Neo-Eunomin that are available?

A: Regulatory documents specify only one fixed dose formulation for this product, which contains Chlormadinone Acetate 2 mg and Ethinyl Estradiol 0.03 mg.

Q: Can Neo-Eunomin cause changes in cholesterol levels?

A: Yes, regulatory data includes changes in serum lipid levels as potential metabolic side effects. This refers to changes in fats in the blood, including total cholesterol, LDL, and HDL.

Q: Is it normal to feel bloated when first starting this medication?

A: Official product information lists abdominal discomfort or bloating as a common side effect. This is often a transient effect experienced as the body adjusts to the hormones.

Q: Are there any known side effects related to eye health, like dry eyes, with Neo-Eunomin?

A: Adverse effects related to vision or the eyes are listed in official documents. For instance, intolerance to contact lenses is listed, often classified as an uncommon side effect.

Q: Is a reduced sex drive a permanent side effect of Neo-Eunomin?

A: Regulatory sources list decreased libido as a common side effect while taking the pill. However, official safety data typically implies that side effects are reversible and usually resolve upon discontinuation of the medication.

Storage Requirements

Neo-Eunomin must be stored under specific environmental conditions as defined by regulatory labeling to maintain the stability of the film-coated tablets. The product must be stored at a temperature no higher than 30°C.

To ensure protection from light and moisture, the medicine must be kept in the original container (blister pack) until use. For safety, Neo-Eunomin is required to be kept out of the sight and reach of children at all times.

Disposal Instructions

Unused or expired Neo-Eunomin must be discarded according to official instructions for pharmaceutical waste. This typically involves returning the medicine to a pharmacy or following local regulations for safe disposal. Medicines must not be thrown away via wastewater or household waste to help protect the environment.